Loading clinical trials...
Loading clinical trials...
A Phase I, Three-Arm Safety, Tolerability, and Pharmacokinetic Interaction Study of PA-824, an Investigational Nitroimidazole for the Treatment of Tuberculosis, Together With Efavirenz, Ritonavir-Boosted Lopinavir, or Rifampin
Conditions
Interventions
PA-824
Efavirenz (EFV)
+2 more
Locations
4
United States
Ucsf Hiv/Aids Crs
San Francisco, California, United States
Johns Hopkins University CRS
Baltimore, Maryland, United States
Ohio State University CRS
Columbus, Ohio, United States
Vanderbilt Therapeutics (VT) CRS
Nashville, Tennessee, United States
Start Date
May 1, 2012
Primary Completion Date
May 1, 2013
Completion Date
May 1, 2013
Last Updated
November 5, 2021
NCT06192160
NCT05947890
NCT05989802
NCT02354014
NCT06272812
NCT04923958
Lead Sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions